About BELKIN Vision
BELKIN Vision is a Healthcare company based in Yavne (Israel) founded in 2013, and was acquired by Alcon in July 2024. Laser device for glaucoma treatment developed by BELKIN Vision. BELKIN Vision has raised $14.75 million across 5 funding rounds from investors including Alcon, Santen Pharmaceuticals and European Union. BELKIN Vision offers products and services including DSLT and Hydrus Microstent. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its legal entity is Alcon Inc.
Company details
BELKIN Vision was founded in 2013 in Yavne, Israel, where a laser device known as Vision DSLT is developed for glaucoma management. The device is designed for non-invasive, non-contact application, delivering laser energy to the limbus to improve intraocular fluid drainage and reduce pressure. Treatment is provided for open-angle and angle-closure glaucoma, with operations focused on medical device innovation in the ophthalmology sector. The companys domain is belkin-vision.com.
- Headquarters Yavne, Israel
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website belkin-vision.com
- Social LinkedIn X
- Acquired by Alcon (Jul 2024)
- Legal Name Alcon Inc.
Products & Services of BELKIN Vision
BELKIN Vision offers a comprehensive portfolio of products and services, including DSLT and Hydrus Microstent.
Delivers laser pulses to treat glaucoma and lower intraocular pressure.
Improves aqueous outflow in glaucoma patients for pressure reduction.
Funding Insights of BELKIN Vision
BELKIN Vision has successfully raised a total of $14.75M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $2.84 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.75M
- Total Rounds 5
- Last Round Grant — $2.84M
- First Round $1.46M
(Sep 2016)
- Investors Count 7
All 5 funding rounds of BELKIN Vision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $2.84M | Grant | – | – | |
| Jul 2020 | $12.25M | Series B | – | Rimonci, Santen Pharmaceuticals | |
| Jun 2017 | $2.5M | Series A | – | Rimonci, Zicom Group | – |
| Jun 2017 | $2.82M | Grant | – | – | |
| Sep 2016 | $1.46M | Grant | – | – |
8 investors in total: 8 institutional.
Investors in BELKIN Vision
BELKIN Vision has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Alcon, Santen Pharmaceuticals and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Limited information is provided about Rimonci's activities. | rimonci.com | |||
ZIG Ventures is focused on healthcare innovation investments. | 2019 | ziggroup.com.sg | Singapore, Singapore | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Diagnostics and therapeutics for ophthalmology | 2005 | bio-light.co.il | Tel Aviv, Israel | |
Pharmaceutical products for ophthalmology and rheumatology diseases are manufactured. | 1890 | santen.com | Osaka, Japan | |
| cmereye.com | ||||
Marine, construction, and automation equipment is manufactured by Zicom Group. | 1970 | zicomgroup.com | Singapore, Singapore | |
Developer of a wide range of eye care products | 1945 | alcon.com | Fort Worth, United States |
Investor details for BELKIN Vision
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BELKIN Vision
32 people are tracked at BELKIN Vision (6 in leadership, 15 in board & advisors, 11 in team).
| Name | Role | Group |
|---|---|---|
Eli Makdasi | COO | Leadership |
Yoram Solberg | VP, Clinical & Medical Affairs | Leadership |
Andrew Webb | Chief Commercial Officer | Leadership |
Michael Belkin | Founder & Medical Director | Leadership |
Tamar Weizman | Director, QA & Regulatory Affairs | Leadership |
Arik Hybloom | Chief Financial Officer | Leadership |
Kuldev Singh | Medical Advisor | Board & advisors |
Thomas Samuelson | Medical Advisor | Board & advisors |
Sarah Van Tassel | Medical Advisor | Board & advisors |
Dennis Lam | Medical Advisor | Board & advisors |
Andy Corley | Chairman, Board of Directors | Board & advisors |
Xing-Huai Sun | Medical Advisor | Board & advisors |
Nate Radcliffe | Medical Advisor | Board & advisors |
Liu Da | Board Member | Board & advisors |
Kok Hwee Sim | Board Member | Board & advisors |
Gus Gazzard | Medical Advisor | Board & advisors |
David Zigdon | Board Member | Board & advisors |
Richel Liu | Board Member | Board & advisors |
Aung Tin | Medical Advisor | Board & advisors |
Richard L. Lindstrom | Chairman, Medical Advisory Board | Board & advisors |
12 more people are available in the full profile.
Complete people profiles for BELKIN Vision
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BELKIN Vision
4 dated milestones of BELKIN Vision across 11 years, from founding to its latest funding, stage changes and deals.
- Founded BELKIN Vision is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Grant, of $2.8M.
- Exit Acquired by Alcon.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Belkin Vision
Complete news archive for BELKIN Vision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BELKIN Vision
BELKIN Vision was founded in 2013 and raised its 1st funding round 3 years after it was founded.
BELKIN Vision is headquartered in Yavne, Israel. It is registered at Yavne, Central District, Israel.
BELKIN Vision is a funded company, having raised a total of $14.75M across 5 funding rounds to date. The company's 1st funding round was a Grant of $1.46M, raised on Sep 2016.
BELKIN Vision was founded in 2013 in Yavne, Israel, where a laser device known as Vision DSLT is developed for glaucoma management. The device is designed for non-invasive, non-contact application, delivering laser energy to the limbus to improve intraocular fluid drainage and reduce pressure. Treatment is provided for open-angle and angle-closure glaucoma, with operations focused on medical device innovation in the ophthalmology sector. The companys domain is belkin-vision.com.
BELKIN Vision offers DSLT and Hydrus Microstent.
BELKIN Vision has 8 investors. Key investors include Alcon, Santen Pharmaceuticals, European Union, BioLight, and Zicom Group.
BELKIN Vision operates through Alcon Inc..
Yes. BELKIN Vision was acquired by Alcon in July 2024.